Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $35 | In Stock | |
5 mg | $89 | In Stock | |
10 mg | $148 | In Stock | |
25 mg | $297 | In Stock | |
50 mg | $588 | In Stock | |
100 mg | $783 | In Stock | |
200 mg | $1,080 | In Stock | |
1 mL x 10 mM (in DMSO) | $88 | In Stock |
Description | Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity. |
Targets&IC50 | JNK3:6 nM, JNK1:61 nM, JNK2:7 nM |
In vitro | Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1 μM)[1] and blocks the JNK pathway activated by pro-fibrotic cytokines in systemic sclerosis[3]. Tanzisertib (CC-930) (1-2 μM) substantially reduces and abrogates apoptosis and necrosis in hepatocytes, including FC-loaded WT hepatocytes[2]. |
In vivo | Tanzisertib (CC-930), when administered orally at doses of 10 and 30 mg/kg, decreases TNFa production by 23% and 77% respectively in the acute rat LPS-induced TNFa production PK-PD model[1]. Additionally, at a dose of 150 mg/kg, Tanzisertib (CC-930) not only prevents the development of fibrosis across various models but also reverses pre-existing fibrosis[3]. |
Alias | CC-930 |
Molecular Weight | 448.44 |
Formula | C21H23F3N6O2 |
Cas No. | 899805-25-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 33 mg/mL (73.59 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.